var data={"title":"Cabergoline: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Cabergoline: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5781?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=cabergoline-patient-drug-information\" class=\"drug drug_patient\">see &quot;Cabergoline: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143938\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>ACT Cabergoline;</li>\n      <li>Dostinex</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143967\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Ergot Derivative</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143941\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hyperprolactinemic disorders:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>US labeling:</i> Initial: 0.25 mg twice weekly; the dose may be increased by 0.25 mg twice weekly up to a maximum of 1 mg twice weekly according to the patient's serum prolactin level. Dosage increases should not occur more rapidly than every 4 weeks. Once a normal serum prolactin level is maintained for 6 months, discontinue cabergoline and monitor prolactin levels to determine if cabergoline should be reinstituted. The durability of efficacy beyond 24 months of therapy has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Canadian labeling:</i> Initial: 0.5 mg once weekly or 0.25 mg twice weekly; weekly dose may be increased by 0.5 mg per week at 4 week intervals until optimal therapeutic response. Therapeutic dose: Usual: 1 mg/week (range: 0.25 to 2 mg/week). Once a normal serum prolactin level is maintained for 6 months, discontinue cabergoline and monitor prolactin levels to determine if cabergoline should be reinstituted. <b>Note:</b> May divide weekly dose into 2 or more divided doses per week (recommended for doses &gt;1 mg/week) based on tolerability.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Lactation inhibition</b> <i>(Canadian labeling; not in US labeling):</i> Oral: 1 mg single dose on first day postpartum</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cushing syndrome (off-label use):</b> Oral: Initial: 0.5 mg once weekly or 1 mg weekly (given as 0.5 mg twice weekly); may increase by 0.5 to 1 mg weekly at 1- or 2-month intervals until complete and sustained normalization of urinary free cortisol (UFC) levels; maximum: 7 mg weekly (given as 1 mg once daily) (ES [Neiman 2015]; Godbout 2010; Pivonello 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Restless legs syndrome (off-label use): </b>Oral: Initial: 0.5 mg, 3 hours before bedtime; titrate in 0.5 mg increments every 3 to 7 days; usual dose: 2 mg; doses as high as 7 mg have been studied (Aurora 2012; Oertel 2006; Stiasny-Kolster 2004; Trenkwalder 2007).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143942\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. Start at the low end of the dosage range.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4117136\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; however, cabergoline pharmacokinetics are not altered in patients with moderate to severe renal impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4117137\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; use with caution and monitor carefully in patients with severe hepatic impairment (Child-Pugh class C) (extensive hepatic metabolism).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143922\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.5 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143909\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13267702\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer with meals (may increase tolerability). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49104437\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 3]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143923\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hyperprolactinemic disorders:</b> Treatment of hyperprolactinemic disorders, either idiopathic or caused by pituitary adenomas.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Limitations of use: Not indicated for inhibition or suppression of physiologic lactation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Canadian labeling:</i> Additional use (not in US labeling): Prevention of the onset of physiological lactation in the puerperium when clinically indicated (eg, still born baby or neonatal death, conditions that interfere with suckling, severe acute or chronic mental illness, maternal disease which may be transmitted to the baby that require medications which are excreted in the milk).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Limitations of use: Not indicated for suppression of already established postpartum lactation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25819768\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Cushing syndrome; Restless legs syndrome</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143916\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&gt;10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Headache (26%), dizziness (15% to 17%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Nausea (27% to 29%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Orthostatic hypotension (4%), hypotension (1%), palpitations (1%), peripheral edema (1%), syncope (1%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Fatigue (5% to 7%), drowsiness (2% to 5%), vertigo (1% to 4%), depression (3%), pain (2%), nervousness (1% to 2%), paresthesia (1% to 2%), anxiety (1%), insomnia (1%), lack of concentration (1%), malaise (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Acne vulgaris (1%), pruritus (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Hot flash (1% to 3%), dependent edema (1%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Constipation (7% to 10%), abdominal pain (5%), dyspepsia (2% to 5%), vomiting (2% to 4%), diarrhea (2%), flatulence (2%), xerostomia (2%), anorexia (1%), toothache (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Mastalgia (1% to 2%), dysmenorrhea (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Weakness (6% to 9%), arthralgia (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ophthalmic: Periorbital edema (1%), visual disturbance (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Flu-like symptoms (1%), rhinitis (1%), throat irritation (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Aggressive behavior, alopecia, cardiac failure (in Parkinson's disease [PD] patients), confusion (in PD patients), constrictive pericarditis (in PD patients), duodenal ulcer (in PD patients), dyskinesia (in PD patients), epistaxis, facial edema, gastric ulcer (in PD patients), hallucination (in PD patients), heart valve disease, increased libido (including hypersexuality), pathological gambling, pleural effusion (in PD patients), psychosis, pulmonary fibrosis (in PD patients), weight gain, weight loss</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143927\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Known hypersensitivity to cabergoline, ergot derivatives, or any component of the formulation; uncontrolled hypertension; history of cardiac valvular disorders (indicated by valvulopathy of any valve, thickening of valve leaflet, valve restriction, or mixed valve restriction stenosis); history of pulmonary, pericardial, or retroperitoneal fibrotic disorders.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143913\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiac valvulopathy: Cardiac valvulopathy has been reported with use. Cardiovascular evaluation (eg. chest x-ray, CT scan, echocardiogram) is necessary prior to initiating treatment; do not start therapy if valvular disease is detected. During treatment, the lowest effective dose should be utilized (incidence may be higher for daily doses &gt;2 mg). Discontinue if an echocardiogram reveals new valvular regurgitation, valvular restriction, or valve leaflet thickening.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiovascular effects: Initial doses &gt;1 mg may cause orthostatic hypotension; may be symptomatic. Use with caution in patients with cardiovascular disease; hypertension, stroke, and seizure have been reported with other dopamine agonists. Concurrent use with antihypertensives may increase risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; CNS depression: May cause somnolence, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pleural/retroperitoneal fibrosis: Cases of pleural, pericardial, and retroperitoneal fibrosis have been reported. Do not use in patients with a history of cardiac or extracardiac fibrotic disorders. Following diagnosis of fibrosis, discontinuation of cabergoline may result in improvement of condition.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Psychiatric disorders: Aggression, psychotic behavior, and impulse control disorders such as pathological gambling, increased libido, hypersexuality, compulsive spending or buying, and binge-eating have been reported with use; generally reversible with dose reduction or discontinuation of treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution and carefully monitor patients with hepatic impairment; extensive hepatic metabolism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Peptic ulcer disease: Use with caution in patients with peptic ulcer disease (PUD) or GI bleeding.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Raynaud syndrome: Use with caution in patients with Raynaud syndrome.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298921\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143918\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8600&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alpha-/Beta-Agonists: Ergot Derivatives may enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha1-Agonists: Ergot Derivatives may enhance the hypertensive effect of Alpha1-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha1-Agonists. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amisulpride: May diminish the therapeutic effect of Cabergoline. Cabergoline may diminish the therapeutic effect of Amisulpride.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antiemetics (5HT3 Antagonists): May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anti-Parkinson Agents (Monoamine Oxidase Inhibitor): May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity if selegiline, rasagiline, or safinamide is combined with a serotonin modulator. Use of transdermal selegiline with serotonin modulators is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents: Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: May enhance the vasoconstricting effect of Ergot Derivatives.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloroprocaine: May enhance the hypertensive effect of Ergot Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clarithromycin: May increase the serum concentration of Cabergoline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapoxetine: May enhance the adverse/toxic effect of Serotonin Modulators.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Linezolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Management: Due to a risk of serotonin syndrome/serotonin toxicity, discontinue serotonin modulators 2 weeks prior to the administration of linezolid. If urgent initiation of linezolid is needed, discontinue serotonin modulators immediately and monitor closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lorcaserin: May enhance the adverse/toxic effect of Ergot Derivatives. Specifically, use of these drugs together may increase the risk of developing valvular heart disease. Lorcaserin may enhance the serotonergic effect of Ergot Derivatives. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metaxalone: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylene Blue: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May enhance the adverse/toxic effect of Serotonin Modulators. Specifically, the risk of serotonin syndrome or serotonin toxicity may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroglycerin: Ergot Derivatives may diminish the vasodilatory effect of Nitroglycerin. This is of particular concern in patients being treated for angina. Nitroglycerin may increase the serum concentration of Ergot Derivatives. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pipamperone [INT]: Cabergoline may diminish the therapeutic effect of Pipamperone [INT]. Pipamperone [INT] may diminish the therapeutic effect of Cabergoline. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Reboxetine: May enhance the hypertensive effect of Ergot Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin 5-HT1D Receptor Agonists: Ergot Derivatives may enhance the vasoconstricting effect of Serotonin 5-HT1D Receptor Agonists. Serotonin 5-HT1D Receptor Agonists may enhance the vasoconstricting effect of Ergot Derivatives. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.<b> Exceptions: </b>Nicergoline; Tedizolid.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulpiride: Cabergoline may diminish the therapeutic effect of Sulpiride. Sulpiride may diminish the therapeutic effect of Cabergoline. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tedizolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TraMADol: Serotonin Modulators may enhance the adverse/toxic effect of TraMADol. The risk of seizures may be increased. TraMADol may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143919\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4116767\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events have not been observed in most animal reproduction studies. Treatment of hyperprolactinemia may restore fertility in previously infertile women. Although available evidence suggests cabergoline use early in pregnancy does not cause harm to the fetus, it is recommended that therapy be discontinued once pregnancy is discovered. If treatment during pregnancy is required, other agents are preferred.  Monitoring of prolactin levels should be suspended during pregnancy (Melmed 2011). Not recommended for use in women with pregnancy-induced hypertension (eg, preeclampsia, eclampsia, postpartum hypertension) unless benefit outweighs potential risk.</p>\n    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">\n      <i>Canadian labeling</i> (not in US labeling): Exclude pregnancy prior to use; prevent pregnancy for &ge;1 month following discontinuation of treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4116770\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if cabergoline is excreted in breast milk. Cabergoline interferes with lactation and should not be given to women postpartum who are breast-feeding or who are planning to breast-feed. In the U.S. labeling, cabergoline is not indicated for the inhibition or suppression of physiologic lactation. Due to the potential for serious adverse reactions in the nursing infant, the manufacturer recommends a decision be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13267701\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Take with food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4117138\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Blood pressure (both sitting/supine and standing); serum prolactin level (monthly until normalized); echocardiogram (at baseline and every 6 to 12 months or as needed during therapy); erythrocyte sedimentation rate, chest x-ray, and serum creatinine (at baseline and during therapy as needed); signs and symptoms of pleuropulmonary disease, renal insufficiency, ureteral/abdominal vascular obstruction, and cardiac failure</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143912\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Cabergoline is a long acting dopamine receptor agonist with a high affinity for D<sub>2</sub> receptors; prolactin secretion by the anterior pituitary is predominantly under hypothalamic inhibitory control exerted through the release of dopamine. It is a potent 5-HT<sub>2B</sub>-receptor agonist, which may contribute to observed fibrotic/valvulopathic events.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143926\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Extensive, particularly to the pituitary </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 40% to 42% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Extensively hepatic via hydrolysis; minimal CYP mediated metabolism</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 63 to 69 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: 2 to 3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Primarily feces (~60%); urine (~22%, &lt;4% as unchanged drug) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143930\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Cabergoline Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg (8): $293.27</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143931\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Alactin (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Alaktyn (UA);</li>\n      <li>Argolin (BD);</li>\n      <li>Cabaser (AR, AU, CH, DK, FI, GB, IE, IL, IT, SE);</li>\n      <li>Cabergoline-Pharmacia (LU);</li>\n      <li>Caberlin (IN, LK);</li>\n      <li>Cabertrix (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Cabexa (HR);</li>\n      <li>Cabolin (BD);</li>\n      <li>Cabotrim (IL);</li>\n      <li>Caverlactin (KR);</li>\n      <li>Dostinex (AE, AR, AT, AU, BE, BG, BH, BR, CH, CL, CO, CR, CY, CZ, DE, DK, DO, EC, EE, EG, ES, FI, FR, GB, GR, GT, HK, HN, IE, IL, IQ, IR, IS, IT, JO, KR, KW, LB, LT, LU, LV, LY, MT, MX, MY, NI, NL, NO, NZ, OM, PA, PE, PL, PT, QA, RO, RU, SA, SE, SG, SI, SK, SV, SY, TR, TW, UA, UY, VE, YE, ZA);</li>\n      <li>Lactinese (PE);</li>\n      <li>Prolastat (CO, EC);</li>\n      <li>Triaspar (AR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aurora RN, Kristo DA, Bista SR, et al. The treatment of restless legs syndrome and periodic limb movement disorder in adults--an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice Guideline. <i>Sleep</i>. 2012;35(8):1039-1062.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/22851801/pubmed\" target=\"_blank\" id=\"22851801\">22851801</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bronstein MD, &ldquo;Prolactinomas and Pregnancy,&rdquo; <i>Pituitary</i>, 2005, 8(1):31-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/16411066/pubmed\" target=\"_blank\" id=\"16411066\">16411066</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cabergoline [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA Inc; November 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dostinex (cabergoline) [prescribing information]. New York, NY: Pfizer; August 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    European Multicentre Study Group for Cabergoline in Lactation Inhibition, &ldquo;Single Dose Cabergoline Versus Bromocriptine in Inhibition of Puerperal Lactation: Randomised, Double-Blind, Multicentre Study,&rdquo; <i>BMJ</i>, 1991, 302(6789):1367-71.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ferrari C, Paracchi A, Mattei AM, et al, &ldquo;Cabergoline in the Long-Term Therapy of Hyperprolactinemic Disorders,&rdquo; <i>Acta Endocrinol (Copenh)</i>, 1992, 126(6):489-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/1642081/pubmed\" target=\"_blank\" id=\"1642081\">1642081</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Garcia-Borreguero D, Ferini-Strambi L, Kohnen R, et al. European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society. <i>Eur J Neurol</i>. 2012;19(11):1385-1396.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/22937989/pubmed\" target=\"_blank\" id=\"22937989\">22937989</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Godbout A, Manavela M, Danilowicz K, Beauregard H, Bruno OD, Lacroix A. Cabergoline monotherapy in the long-term treatment of Cushing's disease. <i>Eur J Endocrinol</i>. 2010;163(5):709-716. doi: 10.1530/EJE-10-0382<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/20702648/pubmed\" target=\"_blank\" id=\"20702648\">20702648</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Giusti M, Porcella E, Carraro A, et al, &ldquo;A Cross-Over Study With the Two Novel Dopaminergic Drugs Cabergoline and Quinagolide in Hyperprolactinemic Patients,&rdquo; <i>J Endocrinol Invest</i>, 1994, 17(1):51-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/7911813/pubmed\" target=\"_blank\" id=\"7911813\">7911813</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Melmed S, Casanueva FF, Hoffman AR, et al; Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2011;96(2):273-288. doi: 10.1210/jc.2010-1692. Review.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/21296991/pubmed\" target=\"_blank\" id=\"21296991\">21296991</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nieman LK, Biller BM, Findling JW, et al; Endocrine Society. Treatment of Cushing&rsquo;s syndrome: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2015;100(8):2807-2831. doi: 10.1210/jc.2015-1818.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/26222757/pubmed\" target=\"_blank\" id=\"26222757\">26222757</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oertel WH, Benes H, Bodenschatz R, et al. Efficacy of cabergoline in restless legs syndrome: a placebo-controlled study with polysomnography (CATOR). <i>Neurology</i>. 2006;67(6):1040-1046.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/16931508/pubmed\" target=\"_blank\" id=\"16931508\">16931508</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pivonello R, De Martino MC, Cappabianca P, et al. The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. <i>J Clin Endocrinol Metab</i>. 2009;94(1):223-230. doi: 10.1210/jc.2008-1533.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/18957500/pubmed\" target=\"_blank\" id=\"18957500\">18957500</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rains CP, Bryson HM, and Fitton A, &ldquo;Cabergoline: A Review of Its Pharmacological Properties and Therapeutic Potential in the Treatment of Hyperprolactinemia and Inhibition of Lactation,&rdquo; <i>Drugs</i>, 1995, 49(2):255-79.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/7729332/pubmed\" target=\"_blank\" id=\"7729332\">7729332</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ricci E, Parazzini F, Motta T, et al, &ldquo;Pregnancy Outcome After Cabergoline Treatment in Early Weeks of Gestation,&rdquo; <i>Reprod Toxicol</i>, 2002, 16(6):791-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/12401507/pubmed\" target=\"_blank\" id=\"12401507\">12401507</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robert E, Musatti L, Piscitelli G, et al, &ldquo;Pregnancy Outcome After Treatment With the Ergot Derivative, Cabergoline,&rdquo; <i>Reprod Toxicol</i>, 1996, 10(4):333-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/8829257/pubmed\" target=\"_blank\" id=\"8829257\">8829257</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roth BL, &ldquo;Drugs and Valvular Heart Disease,&rdquo; <i>N Engl J Med</i>, 2007, 356(1):6-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/17202450/pubmed\" target=\"_blank\" id=\"17202450\">17202450</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schade R, Andersohn F, Suissa S, et al. Dopamine agonists and the risk of cardiac-valve regurgitation. <i>N Engl J Med.</i> 2007;356(1):29-38.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/17202453/pubmed\" target=\"_blank\" id=\"17202453\">17202453</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Scholz H, Trenkwalder C, Kohnen R, Riemann D, Kriston L, Hornyak M. Dopamine agonists for restless legs syndrome. <i>Cochrane Database Syst Rev</i>. 2011;(3):CD006009.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/21412893/pubmed\" target=\"_blank\" id=\"21412893\">21412893</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stiasny-Kolster K, Benes H, Peglau I, et al. Effective cabergoline treatment in idiopathic restless legs syndrome. <i>Neurology</i>. 2004;63(12):2272-2279.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/15623686/pubmed\" target=\"_blank\" id=\"15623686\">15623686</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trenkwalder C, Benes H, Grote L, et al. Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: results from a multi-center, randomized, active controlled trial. <i>Mov Disord</i>. 2007;22(5):696-703.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/17274039/pubmed\" target=\"_blank\" id=\"17274039\">17274039</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Webster J, Piscitelli G, Polli A, et al, &ldquo;A Comparison of Cabergoline and Bromocriptine in the Treatment of Hyperprolactinemic Amenorrhea,&rdquo; <i>N Engl J Med</i>, 1994, 331(14):904-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/7915824/pubmed\" target=\"_blank\" id=\"7915824\">7915824</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Webster J, Piscitelli G, Polli A, et al, &ldquo;Dose-Dependent Suppression of Serum Prolactin by Cabergoline in Hyperprolactinaemia: A Placebo Controlled, Double Blind, Multicentre Study,&rdquo; <i>Clin Endocrinol (Oxf)</i>, 1992, 37(6):534-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/1286524/pubmed\" target=\"_blank\" id=\"1286524\">1286524</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Webster J, Piscitelli G, Polli A, et al, &ldquo;The Efficacy and Tolerability of Long-Term Cabergoline Therapy in Hyperprolactinaemic Disorders: An Open, Uncontrolled, Multicentre Study,&rdquo; <i>Clin Endocrinol (Oxf)</i>, 1993, 39(3):323-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/7900937/pubmed\" target=\"_blank\" id=\"7900937\">7900937</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Winkelman JW, Armstrong MJ, Allen RP, et al. Practice guideline summary: treatment of restless legs syndrome in adults: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. <i>Neurology.</i> 2016;87(24):2585-2593. doi: 10.1212/WNL.0000000000003388.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/27856776/pubmed\" target=\"_blank\" id=\"27856776\">27856776</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zanettini R, Antonini A, Gatto G, et al, &ldquo;Valvular Heart Disease and the Use of Dopamine Agonists for Parkinson&rsquo;s Disease,&rdquo; <i>N Engl J Med</i>2007, 356(1):39-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cabergoline-drug-information/abstract-text/17202454/pubmed\" target=\"_blank\" id=\"17202454\">17202454</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8600 Version 146.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F143938\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F143967\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F143941\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F143942\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F4117136\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F4117137\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F143922\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F143909\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F13267702\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49104437\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F143923\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25819768\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F143916\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F143927\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F143913\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298921\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F143918\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F143919\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F4116767\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F4116770\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F13267701\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F4117138\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F143912\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F143926\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F143930\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F143931\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8600|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=cabergoline-patient-drug-information\" class=\"drug drug_patient\">Cabergoline: Patient drug information</a></li></ul></div></div>","javascript":null}